BAVENCIO (Avelumab) prices

1,215.00

If you want to buy the drug BAVENCIO (Avelumab), contact us by e-mail aptekarprovizor@gmail.com

We buy drugs in pharmacies in Germany

Категория: Метки: ,

Описание

BAVENCIO (Avelumab)

Dosage Forms & Strengths

solution for injection

  • 20mg/mL (200mg/10mL vial)

Merkel Cell Carcinoma

Indicated for metastatic Merkel cell carcinoma (MCC) in adults and pediatric patients aged ≥12 yr

10 mg/kg IV q2wk

Continue until disease progression or unacceptable toxicity

Also see Administration

Urothelial Carcinoma

Indicated for locally advanced or metastatic urothelial carcinoma (UC) in patients who have disease progression during or following platinum-containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

10 mg/kg IV q2wk

Continue until disease progression or unacceptable toxicity

Also see Administration

Dosage Modifications

Withhold for any of the following (may resume when recover to grade 0-1)

  • Grade 2 pneumonitis
  • Grade 2 or 3 diarrhea or colitis
  • Grade 3 or 4 endocrinopathies
  • Serum creatinine >1.5 and up to 6 x ULN AST or ALT >3 and up to 5 x ULN or total bilirubin >1.4 and up to 3 x ULN
  • Any other severe or grade 3 treatment-related adverse reaction

Permanently discontinue for any of the following

  • Any life-threatening adverse reaction (excluding endocrinopathies controlled with hormone replacement therapy)
  • Grade 3 or 4 pneumonitis or recurrent grade 2 pneumonitis
  • Grade 4 diarrhea or colitis or recurrent grade 3 diarrhea or colitis
  • Serum creatinine >6 x ULN AST or ALT >5 x ULN or total bilirubin >3 x ULN
  • Grade 3 or 4 infusion-related reactions
  • Inability to reduce corticosteroid dose to ≤10 mg/day of prednisone or equivalent within 12 weeks
  • Persistent grade 2 or 3 adverse reactions that do not recover to grade 0-1 within 12 weeks after last dose
  • Any severe or grade 3 treatment-related adverse reaction that recurs

Based on its mechanism of action, BAVENCIO can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. If this drug is used during pregnancy, or if the patient becomes pregnant while taking BAVENCIO, inform the patient of the potential risk to a fetus. Advise females of childbearing potential to use effective contraception during treatment with BAVENCIO and for at least one month after the last dose of BAVENCIO

Обзоры

Отзывов пока нет.

Будьте первым, кто оставил отзыв на “BAVENCIO (Avelumab)... ”

Ваш e-mail не будет опубликован. Обязательные поля помечены *